John Marshall, MD, discusses the individualization of treatment of patients with colorectal cancer (CRC).
John Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, discusses the individualization of treatment of patients with colorectal cancer (CRC). Marshall says while maintaining VEGF-inhibition does promote a better overall survival advantage, there is not a major difference between many of the frontline therapies. He adds that the order in which medical professionals decide to use these treatments is entirely up to the individual and based on what the patient responds to.
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More